Evidence map›Paper›PMID 41613479›Full record

ArticleFundamental research2025

Detection of the characteristic magnetic signal of paclitaxel and its application in the inhibition of glioma cells.

Yinhui Deng, Quan Tao, Qisheng Tang, Yinlong Liu, Hui Dong, Zhifeng Shi, Xiaoming Xie, Weiqi Wang, Liangfu Zhou, Jinhua Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fundamental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yinhui DengBiomedical Engineering Center, School of Information Science and Technology, Fudan University, Shanghai 200433, China.
Quan TaoShanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai 200050, China.
Qisheng TangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 201100, China.
Yinlong LiuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 201100, China.
Hui DongShanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai 200050, China.
Zhifeng ShiDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 201100, China.
Xiaoming XieShanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai 200050, China.
Weiqi WangBiomedical Engineering Center, School of Information Science and Technology, Fudan University, Shanghai 200433, China.
Liangfu ZhouDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 201100, China.
Jinhua YuBiomedical Engineering Center, School of Information Science and Technology, Fudan University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma, a type of brain tumor, is one of the most challenging cancers for human beings due to its genetic heterogeneity, high recurrence rate and difficulty of effective treatment. To explore a novel treatment method for glioma, a scientific hypothesis was proposed that a chemical substance or biological agent may generate a characteristic magnetic signal, and this signal is the fundamental reason that the chemical substance or biological agent works for cancer treatment. Based on this hypothesis, a superconducting quantum interference device (SQUID) using the stochastic resonance (SR) method was established, and the characteristic magnetic signal of paclitaxel was detected and clearly visualized for the first time. Then, cell experimental results demonstrated that the detected characteristic magnetic signal of paclitaxel was as effective as paclitaxel for the inhibition of glioma cells. Our study suggested that the application of paclitaxel's characteristic magnetic signal might provide an ideal treatment direction for glioma patients due to its lack of side effects, high focusable penetration and effectiveness.

Indexed as

Characteristic magnetic signalGliomaPaclitaxelStochastic resonanceSuperconducting quantum interference device

Identifiers

PMID41613479
PMCPMC12848243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.